Previous 10 | Next 10 |
The CHMP adopted two positive opinions recommending European Commission approval of: REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant IMNOVID in combination with bort...
The bearish options bets against the completion of the Celgene ( CELG ) and Bristol-Myers ( BMY ) deal continue to build. Just over the past few days, there has been an increasing number of bearish bets placed suggesting that the deal may not be completed. On March 13, I noted Options Betti...
Quick Take Turning Point Therapeutics ( TPTX ) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing small molecule, targeted oncology therapies for various cancers. TPTX is preparing to enter Phase 2 trials ...
The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...
Bristol-Myers Squibb (NYSE: BMY ) discloses that it and acquisition target Celgene (NASDAQ: CELG ) have received requests from the U.S. Federal Trade Commission (FTC) for additional information and documents related to the proposed merger. The FTC is looking specifically at marketed and pi...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
Merger activity remained unchanged last week with three new deals announced, two pending deals closing and one deal falling apart. Deal Statistics New Deals The acquisition of Worldpay ( WP ) by Fidelity National Information Services ( FIS ) for $43 billion in a cash-plus-stock deal...
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P)...
When Celgene ( CELG ) and Bristol-Myers Squibb ( BMY ) announced their mega-merger just days after the new year, it shocked the entire pharma world. Their deal, valued at $74 billion, would be the largest ever in pharma history and create a combined company that would be the 4 th largest ...
In a letter to shareholders, Bristol-Myers Squibb (NYSE: BMY ) reiterates the benefits of its $74B bid for Celgene (NASDAQ: CELG ). Key points: More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Merger & acquisition news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...